AzTrials
AzTrials

Gestational Diabetes MellitusNCT02649374

Gut Microbiome and Gestational Diabetes Mellitus

A study testing Dietary, Exercise and lifestyle modifications in people with Gestational Diabetes Mellitus, run by Rabin Medical Center at 1 site in Israel.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to document the gut microbiome in the 1st, 2nd and 3rd trimester among pregnant women with gestational diabetes and non diabetic controls. Read more about this study

Who is it for?
Ages 18 to 45 years, women only
Conditions the study is for
Gestational Diabetes Mellitus
What is being tested?
Dietary, Exercise and lifestyle modifications
Could I receive a placebo?
No, everyone receives an active treatment
How many people
400 participants
Where
1 siteIsrael
Study dates
Feb 2016to 10 Dec 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • 1. Pregnant women at the 1st trimester

Who cannot join

  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus
  • Post Bariatric surgery
  • Any concurrent chronic illness or medication use
  • Any use of hormones or antibiotics within prior 3 months
  • Multiple gestation

Trial locations and contacts

1 site in 1 country.

Israel1 site
  • Rabin Medical Center

    Petah Tikva, 49100

Other trials in Israel

About this study

The purpose of this study is to document the gut microbiome in the 1st, 2nd and 3rd trimester among pregnant women with gestational diabetes and non diabetic controls.

Read the detailed description

The gut microbiome:

The human body is colonized by a multitude of microorganisms whose collective genome, the microbiome, complements and enhances our own genome. From this perspective, humans are "supra-organisms" colonized by a number of microbial cells that is 10 times greater than the sum of all our human somatic and germ cells, and carrying 150 times more genetic information. The intestine contains the largest collection of microbes among all of our body's "habitats". In the colon, for example, bacteria reach densities of 1011 cells per gram of luminal contents. Together, gut microbes form a community, or microbiota, that has a major impact on health through interactions with host cells (including components of the innate and adaptive immune systems), through extraction of nutrients and energy from the diet, and through complex biotransformations of a variety of ingested compounds, including potential carcinogens. One of the main measures tested when analyzing bacterial populations is diversity - identifying the different microbial components in the population, and describing how similar they are to one another (according to phylogeny) both within a sample and between samples.

Changes in the gut microbiome: The majority of gut microbes are generally viewed as beneficial symbionts, but recent work has revealed that the wrong combination of beneficial microbes can be harmful. Shifts in the composition of the microbiome occur at different stages in life, such as childhood, aging, and pregnancy. Changes in the composition (dysbiosis) are also associated with a growing list of diseases, such as obesity, inflammatory bowel disease (IBD), diabetes, metabolic syndrome and others. Such associations raise the question of whether the dysbiosis contributes to, or is, a symptom of the disease. Microbiome transplant experiments have demonstrated a role of the microbiome in several diseases: several phenotypes could be transferred via the microbiota, such as enhanced fat gain, metabolic syndrome, colitis and recently, fecal transplantation from lean human subjects to human subjects with metabolic syndrome was shown to increase insulin sensitivity. Fecal transplantations have also been used successfully to treat IBD patients. Together these transplantation-based studies imply that the specific composition of the microbiota can be an important factor in the onset, and possibly the progression of chronic diseases. Thus, the gut microbiota may be considered, by extension, a factor in host fitness.

Diet and the microbiome: One of the factors that most influences the composition of the microbiome is diet. Changes in diet influence the relative abundance and composition of the microbiota almost immediately, but for these compositional changes to become stable, the dietary change has to be long term. A few examples of recent studies on how the diet impacts the microbiota are mentioned below. In humans, an increase in the ratio of Bacteroidetes/Firmicutes is observed when restricting the calorie/carbohydrate content. Reduced dietary intake of carbohydrates has also been shown to result in decreased concentrations of butyrate producing bacteria. The type and quantity of dietary fat and carbohydrate have also been shown to alter the gut microbiome of people with metabolic syndrome. Other bacteria, Prevotella for example, are associated with high intake of carbohydrates and simple sugars.

A diet high in fiber has been shown to be associated with an increase in Bifidobacterium, Lactobacillus, Enterococcus and Ruminococcus. Ruminococcus was also shown to increase in abundance in subjects on a resistant starch diet. Changes due to diet have also been described in mice. For example, a high fat diet can profoundly alter the composition of the microbiota towards an enrichment of Firmicutes.

The female microbiome: Women go through several major physiological transitions during their lifetime, beginning with puberty, followed by conception, pregnancy and finally menopause. During these changes the female body undergoes hormonal, metabolic, immunological changes, and changes in the microbiome.In a pioneering study the investigators recently showed that gut microbiota is profoundly altered in pregnancy (and changes dramatically during gestation) as compared to that in non-pregnant women. Together with what the investigators know about changes in the female vaginal microbiome (reduced microbial richness and diversity in pregnancy along with an enrichment of Lactobacilli) and other microbial changes that are unique to women (such as dramatic shifts in hormonal levels) - ] the investigators expect that different pathologies will be correlated with alterations in the microbiome.

In the proposed research, the investigators aim to test whether there is a correlation between gestational diabetes melitus and changes in the microbiome, as well as when the changes started and how glucose balance with diet changes will alter the microbiome.

The aims of the study:

  1. To find out the differences in the microbiome composition between trimesters in healthy pregnant women
  2. To find out the differences in the microbiome composition between GDM and healthy pregnant women during all trimesters
  3. To find out the differences in the microbiome composition between balanced sugar GDM with diet and healthy women (without GDM) from GDM diagnosis till third trimester
Being tested
Dietary, Exercise and lifestyle modifications
Medical subject headings
Diabetes, Gestational

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dietary, Exercise and lifestyle modificationsBehavioural

    Women without GDM will receive advise on diet, exercise and lifestyle modifications similar to what is advised to women with GDM

Study groups in NCT02649374
Study groupRoleWhat they receive
Gestational diabetes mellitusNo interventionwomen diagnosed with GDM during pregnancy, either treated by diet or pharmacological therapy
No GDM, Dietary ModificationsActive comparatorWomen without GDM, will be advised and monitored for dietary, Exercise and lifestyle modifications
Receives: Behavioral: Dietary, Exercise and lifestyle modifications
No GDM, free dietNo interventionWomen without GDM, for whom diet. exercise are continued regulary without any modifications

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Bacterial population diversity

    It is a descriptive outcome descibint the physiological composition of the gut and oral microbiome. The microbiome population will be quantified by DNA analysis of the samples collected throughout pregnancy from the oral cavity and stool . The precentage of each baceria colonizing the gut and oral cavitiy will be reported

    Measured: 9 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jan 2016 (estimated)
  2. Study startFeb 2016
  3. Primary completion10 Dec 2018
  4. Study completion10 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
400 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02649374
Sponsor's protocol ID
0263-15-RMC
Status last verified
Sep 2019
First submitted
23 Dec 2015
Last updated
12 Sep 2019
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Dietary, Exercise and lifestyle modifications in people with Gestational Diabetes Mellitus, run by Rabin Medical Center at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Bacterial population diversity (time frame: 9 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in